01598nas a2200349   4500000000100000008004100001260001300042653001500055653001000070653000900080653001200089653001200101653002000113653001100133653001100144653001200155653000900167653000900176653001600185653001300201100001500214700001600229700001600245700001300261700001600274245004800290856004100338300001100379490000700390520083700397022001401234       1996                            d  c1996 Jun10aAdolescent10aAdult10aAged10aAnimals10aDapsone10aDrug Resistance10aFemale10aHumans10aleprosy10aMale10aMice10aMiddle Aged10aRifampin1 aButlin C R1 aNeupane K D1 aFailbus S S1 aMorgan A1 aBritton W J00aDrug resistance in Nepali leprosy patients.  uhttp://ila.ilsl.br/pdfs/v64n2a07.pdf  a136-410 v643 a<p>Although multidrug therapy (MDT) was introduced into Nepal in 1983, the MDT coverage only recently exceeded 67%. In view of the large number of patients who were still receiving dapsone monotherapy, it is relevant to investigate the current levels of dapsone and rifampin resistance. The study was undertaken at a leprosy referral hospital near Kathmandu. Over a 5 1/2-year period, 157 leprosy patients with a bacterial index (BI) > or = 2.0 were investigated for drug resistance according to the method of Rees. Among previously untreated cases, 6% of 88 isolates showed low-dose dapsone resistance; among previously treated patients with a presumed relapse, 47% of 34 isolates demonstrated dapsone resistance. In the remaining 35 cases there was no growth in control mice. Rifampin resistance was not confirmed in any case.</p>  a0148-916X